During the relapsing phase of MS, elevated STAT3 activation levels may correlate with diminished SOCS3 expression—which typically inhibits STAT3 activation—potentially leading to hyperactivation of STAT3 associated with disease relapses (48). This evidence concerns the gene STAT3 and myeloid sarcoma.